Volume 24, Issue 105, September - October, 2020

Value of plasma NGAL in the 12-month all-cause mortality prognosis of acute heart failure or acute decompensated heart failure

Hao Thai Phan^1♦, Tien Anh Hoang², Bao Bui Hoang³, Minh Van Huynh⁴

¹Master in Internal Medicine, MD; Pham Ngoc Thach University of Medicine; PhD Student of Hue University of Medicine and Pharmacy, Hue University, Vietnam. Email: phanthaihao@yahoo.com
²Asssociated Professor, PhD, MD; Hue University of Medicine and Pharmacy, Hue University, Vietnam; Email: bsanhtien@yahoo.com
³Asssociated Professor, PhD, MD; Hue University of Medicine and Pharmacy, Hue University, Vietnam; Email: bsbao@yahoo.com
⁴Professor, PhD, MD; Hue University of Medicine and Pharmacy, Hue University, Vietnam; Email: dr.hvminh@gmail.com

^♦Corresponding author
Department of Internal Medicine, Faculty of Medicine, Pham Ngoc Thach University of Medicine, 2 Duong Quang Trung, Ward 12, District 10, Ho Chi Minh city, Vietnam; Email: phanthaihao@yahoo.com; haopt@pnt.edu.vn

ABSTRACT

Background: The presence of acute kidney injury in the setting of acute heart failure (AHF) or acute decompensated heart failure (ADHF) is very popular and was called cardiorenal syndrome 1 (CRS1). CRS1 is associated with significant morbidity and mortality. Neutrophil gelatinase-associated lipocalin (NGAL) is an early predictor of acute kidney injury and poor outcomes in various diseases; though, in AHF or ADHF patients, its significance remains poorly understood. This study was aimed to evaluate the 12 month prognostic value of plasma NGAL in AHF or ADHF patients. Methods: There were 139 patients with AHF or ADHF in the department of cardiovascular resuscitation and Interventional cardiology at Ho Chi Minh City 115 People Hospital from September 2018 to March 2019 and 12 months follow-up. A prospective cohort study was carried out. Results: There were 46 all-cause mortality cases (rate 33.1%) 12 months follow up after discharge. There were 11 cases (rate 7.9%) lost to follow-up; mean age 66.12 ± 15.77, men accounted for 50.4%. The optimal cut-off of NGAL for 12-month all-cause mortality prognosis was> 383.74 ng/ml, AUC 0.632 (95% CI 0.53-0.74, p = 0.011), sensitivity 58.7 %, specificity 68.29 %, negative predictive value 74.7%, positive predictive value 50.9%. Kaplan-Meier analysis revealed that the high plasma NGAL (≥ 400 ng/ml) group exhibited a worse prognosis than the low plasma NGAL (< 400 ng/ml) group in 12-month all-cause death (Hazard Ratio 2.56; 95%CI 1.35-4.84, P=0.0039. Independent predictors of 12-month all-cause-mortality were identified using multivariable Cox proportional-hazards regression models with backwardstepwise selection method consisted of two variables: level of NGAL, mechanical ventilation at admission. Conclusions: Plasma NGAL and mechanical ventilation at admissions were independent predictors of 12-month all-cause mortality in patients with AHF or ADHF. The survival probability 12-month follow-up of high level NGAL (≥ 400 ng/ml) groups were lower than that of low level NGAL (<400 ng/ml), difference was statistically significant χ2 = 8.31; p = 0.0047 by Kaplan-Meier curve.

Keywords: Neutrophil Gelatinase-Associated Lipocalin (NGAL), Cardio-Renal Syndrome (CRS1) Type 1, biomarkers, 12-month mortality prognosis

Medical Science, 2020, 24(105), 3385-3394

PDF